ADAM, a disintegrin and metalloproteinases; AGE, advanced glycation end products; Angiogenesis; Cancer; Collagen; DDR1, discoidin domain receptor 1; ECM, extracellular matrix; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; EMILIN1, elastin microfibril interfacer 1; EMILIN2, elastin microfibril interfacer 2; EMT, epithelial-mesenchymal transition; ERα, estrogen receptor α; ERß, estrogen receptor ß; GBM, glioblastoma; HA, hyaluronan; HAS2, hyaluronan synthase 2; HAS2-AS1, HAS2 antisense 1; HB-EGF, heparin binding EGF; HMGA2, high-mobility group AT-Hook 2; IBC, inflammatory breast cancer; IGF-IR, insulin growth factor I receptor; IR-A, insulin receptor A; LEKTI, lympho-epithelial Kazal-type inhibitor; LOX, lysyl oxidases; LTBP, latent TGFß-binding proteins; MAGP, microfibril-associated glycoproteins; MET, mesenchymal-epithelial transition; MMP, matrix metalloproteinases; Methodologies; OB, osteoblast; OI, osteogenesis imperfecta; PARs, protease activated receptors; PG, proteoglycans; PLL, poly-l-lysine; Proteoglycans; ROS, reactive oxygen species; RTK, receptor tyrosine kinase; SLRP, small leucine rich proteoglycans; SSR, solar-simulated radiation; TGFß, transforming growth factor ß; TNT, tunneling nanotubes; UVR, ultraviolet radiation; VEGF, vascular endothelial growth factor; miR, microRNA; tPA, tissue-type plasminogen activator; uPA, urokinase-type plasminogen activator